Reference
1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus
Disease 2019 in China. N Engl J Med. 2020.
2. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
Wuhan, China. JAMA. 2020.
3. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the
recognition of SARS-CoV-2 by full-length human ACE2. Science.2020;367(6485):1444-1448.
4. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA,
Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients
with Covid-19. N Engl J Med. 2020;382(17):1653-1659.
5. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of
Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor
Blockers with Mortality Among Patients With Hypertension Hospitalized
With COVID-19. Circ Res. 2020.
6. Ferrario CM, Jessup J, Chappell MC, et al. Effect of
angiotensin-converting enzyme inhibition and angiotensin II receptor
blockers on cardiac angiotensin-converting enzyme 2. Circulation.2005;111(20):2605-2610.
7. Mazzolai L, Burnier M. Comparative safety and tolerability of
angiotensin II receptor antagonists. Drug Saf. 1999;21(1):23-33.
8. World Health Organization. Coronavirus disease (COVID-19) technical
guidance: laboratory testing for 2019-nCoV in humans 2020.
9. Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of
ARDS: an expanded rationale, justification, and supplementary material.Intensive Care Med. 2012;38(10):1573-1582.
10. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the
diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected
pneumonia (standard version). Mil Med Res. 2020;7(1):4.
11. Khwaja A. KDIGO clinical practice guidelines for acute kidney
injury. Nephron Clin Pract. 2012;120(4):c179-184.
12. European Association for the Study of the Liver. Electronic address
eee, Clinical Practice Guideline Panel C, Panel m, representative EGB.
EASL Clinical Practice Guidelines: Drug-induced liver injury. J
Hepatol. 2019;70(6):1222-1261.
13. Burnier M, Brunner HR. Angiotensin II receptor antagonists.Lancet. 2000;355(9204):637-645.
14. Juyi Li, Xiufang Wang, Jian Chen, et al. Association of
Renin-Angiotensin System Inhibitors With Severity or Risk of Death in
Patients With Hypertension Hospitalized for Coronavirus Disease 2019
(COVID-19) Infection in Wuhan, China. JAMA Cardiol. Published
online April 23, 2020. doi:10.1001/jamacardio.2020.1624
15. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D.
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
Glycoprotein. Cell. 2020;181(2):281-292 e286.
16. Cheng H, Wang Y, Wang GQ. Organ-protective effect of
angiotensin-converting enzyme 2 and its effect on the prognosis of
COVID-19. J Med Virol. 2020.
17. Sriram K, Insel PA. Risks of ACE inhibitor and ARB usage in
COVID-19: evaluating the evidence. Clin Pharmacol Ther. 2020.
18. Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting
enzyme 2 accelerates maladaptive left ventricular remodeling in response
to myocardial infarction. Circ Heart Fail. 2009;2(5):446-455.
19. Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits
lung injury induced by respiratory syncytial virus. Sci Rep.2016;6:19840.
20. Hamming I, van Goor H, Turner AJ, et al. Differential regulation of
renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition
and dietary sodium restriction in healthy rats. Exp Physiol.2008;93(5):631-638.
21. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D.
Localization of ACE2 in the renal vasculature: amplification by
angiotensin II type 1 receptor blockade using telmisartan. Am J
Physiol Renal Physiol. 2009;296(2):F398-405.
22. Wang X, Ye Y, Gong H, et al. The effects of different angiotensin II
type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and
ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling
in male mice. J Mol Cell Cardiol. 2016;97:180-190.
23. Lely AT, Hamming I, van Goor H, Navis GJ. Renal ACE2 expression in
human kidney disease. J Pathol. 2004;204(5):587-593.
24. Lu N, Yang Y, Wang Y, et al. ACE2 gene polymorphism and essential
hypertension: an updated meta-analysis involving 11,051 subjects.Mol Biol Rep. 2012;39(6):6581-6589.
25. Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the
novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different
populations. Cell Discov. 2020;6:11.